L 657743

structure given in first source

Also Known As:

1',3'-dimethylspiro(1,3,4,5',6,6',7,12b-octahydro-2H-benzo(b)furo(2,3-a)quinolizine)-2,4'-pyrimidin-2'-one; L 657,743; L-657,743; L-657,743-002W; MK 912; MK-912

Networked: 9 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolizines: 1
      - L 657743: 9

Experts

1.	Stepanović-Petrović, Radica M: 2 articles (12/2012 - 11/2007)
2.	Tomić, Maja A: 2 articles (12/2012 - 11/2007)
3.	Micov, Ana M: 1 article (12/2012)
4.	Ugrešić, Nenad D: 1 article (12/2012)
5.	Bosković, Bogdan: 1 article (11/2007)
6.	Paranos, Sonja Lj: 1 article (11/2007)
7.	Prostran, Milica S: 1 article (11/2007)
8.	Ugresić, Nenad D: 1 article (11/2007)
9.	Vucković, Sonja M: 1 article (11/2007)
10.	Arnsten, Amy F T: 1 article (07/2002)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 11/01/1991 - "Ten asymptomatic patients with NIDDM received either a single oral dose of MK-912 (2 mg) or placebo in a double-blind, cross-over study. " 11/01/1991 - "We used MK-912, a potent new selective alpha 2-adrenergic receptor antagonist that is active orally, to study the effect of short-term, selective alpha 2-blockade on fasting plasma glucose (FPG) and pancreatic islet function in non-insulin-dependent diabetes (NIDDM). "
2.	Mydriasis 04/01/1988 - "In tests carried out in vivo with rats for ascertaining alpha-2 adrenoceptor antagonism in the central nervous system--namely, accumulation of cortical dopa and antagonism of mydriasis induced by the alpha-2 agonist, clonidine--L-659,066 had, respectively, less than 1/345th and about 1/5000th of the potency of L-657,743. " 08/01/1987 - "In vivo, L-657,743 potently blocked clonidine-induced mydriasis in the rat and stimulated cerebrocortical norepinephrine synthesis, two indices of central alpha 2-adrenoceptor antagonism. "
3.	Xerostomia 07/01/1989 - "The 2 mg dose of MK-912 significantly inhibited the clonidine-induced hypotension, bradycardia, xerostomia, and increase in plasma glucose concentrations that were observed during the placebo treatment period (p less than 0.05). "
4.	Vomiting 01/01/2001 - "Pre-treatment with yohimbine, MK-912 or MK-467 (alpha(2)-adrenoceptor antagonists) caused sudden and unexpected vomiting. "
5.	Pain (Aches) 11/01/2007 - "We studied whether peripheral alpha2-adrenergic receptors are involved in the antihyperalgesic effects of oxcarbazepine by examining the effects of yohimbine (selective alpha2-adrenoceptor antagonist), BRL 44408 (selective alpha(2A)-adrenoceptor antagonist), MK-912 (selective alpha2C-adrenoceptor antagonist), and clonidine (alpha2-adrenoceptor agonist) on the antihyperalgesic effect of oxcarbazepine in the rat model of inflammatory pain. "

Related Drugs and Biologics

1.	Glucose (Dextrose)
2.	Insulin (Novolin)
3.	Clonidine (ST 155)
4.	Yohimbine (Yocon)
5.	Adrenergic Receptors (Adrenergic Receptor)
6.	BRL 44408
7.	Purinergic P1 Receptor Antagonists
8.	GABA-A Receptor Antagonists
9.	Idazoxan
10.	Guanfacine (Tenex)

Related Therapies and Procedures

1.	Controlled Hypotension